KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiDiscretamente calibratoProbabilità implicita attuale
Sì 79%
Qualità del mercato
43 / 100
Bassa qualitàVolume 24h
—
Liquidità
437,3 €
Bassa liquiditàBid / Ask
78.0% / 84.0%
Spread
6.0 pt
Spread ampioDati di mercato
Aggiornato 5 minuti fa
17 giu 26, 21:00 UTC1 gen 27, 04:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiEbola pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketNew pandemic in 2026?
PolymarketRegole
If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Si regola tramite:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact.
- It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme.
- Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.
Mercati aperti
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 18,3K €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume totale
- 1,6 Mln €
- Volume 24h
- 5,2K €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 altri esiti
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume totale
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume totale
- 916K €
- Volume 24h
- 1,5K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 altri esiti
- Volume totale
- 863,6K €
- Volume 24h
- 1K €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Domande frequenti
- Quali sono le probabilità attuali per FDA decision: Venglustat by Sanofi (in 2026)?
- Kalshi quota Yes al 79% al 8 settembre 2026.
- Quando si risolve FDA decision: Venglustat by Sanofi (in 2026)?
- FDA decision: Venglustat by Sanofi (in 2026) dovrebbe risolversi il 1 gennaio 2027.
- Come viene liquidato FDA decision: Venglustat by Sanofi (in 2026)?
- Kalshi liquida questo mercato come segue: If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.